SCHEMBL5842465

SCHEMBL5842465

CCn1c2ccccc2c2cc(NC(=O)C3CC(=O)N(c4ccccc4)C3)ccc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.56
MAPT P10636 6/20 0.54
KDM4E B2RXH2 4/20 0.54
LMNA P02545 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA4 P22748 2/20 0.54
CA6 P23280 2/20 0.54
CA7 P43166 2/20 0.54
CA13 Q8N1Q1 2/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
REV1 Q9UBZ9 1/20 0.53
ROCK2 O75116 1/20 0.53
ROCK1 Q13464 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5841789 0.93 SMN1; SMN2 (0.58) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL27617658 0.93 MEN1 (0.62) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5841644 0.91 MAPT (0.61) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5843062 0.91 MEN1 (0.55) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5842953 0.91 TP53 (0.61) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5844481 0.88 NPY5R (0.54) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5842206 0.85 MAPT (0.53) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5842506 0.85 MAPT (0.53) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5842917 0.85 MAPT (0.53) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL27599166 0.85 POLB (0.64) NPSR1MAPTKDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100534990-C Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN claimed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US claimed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US claimed
CN-1610678-A Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2005-04-27 CN claimed
CN-100534990-C Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 CN disclosed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed
CN-1610678-A Pyrrolidone carboxamides ACTELION PHARMACEUTICALS LTD (CH) 2005-04-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R NPSR1 24/4885MAPT 4395/4885KDM4E 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.